Market Place
Sourcing Support
Neurana concludes subject enrolment in trial of muscle spasm therapy
30 Nov 2021 //
CLINICALTRIALSARENA
DCGI asks to restrict use of tolperisone FDC to post stroke spasticity only
03 Sep 2021 //
PHARMABIZ
Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week
30 Aug 2021 //
PRNEWSWIRE
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study
07 Jun 2021 //
PRNEWSWIRE
Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS
08 Dec 2020 //
PRNEWSWIRE
Neurana Pharma announces positive results from phase 2 STAR study of tolperisone
25 Sep 2019 //
PHARMABIZ
Katama Receives a Notice of Allowance of a Composition of Matter Patent
09 Mar 2016 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.